B
Barry C. Fox
Researcher at Ohio State University
Publications - 5
Citations - 1188
Barry C. Fox is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 3, co-authored 3 publications receiving 1169 citations.
Papers
More filters
Journal ArticleDOI
A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation
Jesse L. Goodman,Drew J. Winston,Ronald A. Greenfield,Pranatharthi H. Chandrasekar,Barry C. Fox,Herbert Kaizer,Richard K. Shadduck,Thomas C. Shea,Patrick J. Stiff,David J. Friedman,William G. Powderly,Jeffrey L. Silber,Harold W. Horowitz,Alan E. Lichtin,Steven N. Wolff,Mangan Kf,Samuel M. Silver,Daniel J. Weisdorf,Winston G. Ho,Gene S. Gilbert,Donald N. Buell +20 more
TL;DR: Prophylactic administration of fluconazole to recipients of bone marrow transplants reduces the incidence of both systemic and superficial fungal infections.
Journal ArticleDOI
Rapid-onset reversible ocular toxicity from ethambutol therapy.
Harris S. Schild,Barry C. Fox +1 more
Journal ArticleDOI
Heavy contamination of operating room air by Penicillium species: Identification of the source and attempts at decontamination
TL;DR: It is believed that certification guidelines are highly desirable for hospital ventilation systems, especially if the system serves immunocompromised patients, as contamination eventually recurred and required repeated decontamination.
Journal ArticleDOI
Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints
TL;DR: Fluoroquinolone resistance has been underreported in Wisconsin as a whole, yet geographic variability continues to exist, and targeted annual surveillance is important to identify and monitor resistance trending.
Journal ArticleDOI
Changes in Streptococcus pneumoniae Susceptibility in Wisconsin: Implications for Clinical Treatment Decisions for Respiratory Infections
TL;DR: In this paper , the American Thoracic Society and Infectious Diseases Society of America updated clinical practice guidelines for community-acquired pneumonia (CAP) and made a conditional recommendation for macrolide monotherapy for outpatients based on resistance levels.